Detailed financial statements for Elicio Therapeutics, Inc. (ELTX): income statement, balance sheet and cash-flow summary. Track margins, debt, liquidity and profitability trends year over year with up to 20 years of history.
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers.
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $1.77, ELTX has negative trailing earnings (P/E not meaningful) and an ROE of -12.66%. Market capitalisation stands at $34M.
Balance sheet quality for ELTX: current ratio of 2.4, net cash position of $4.1M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Income Statement (10y)
| Year | 2012 | 2013 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.3M | $6.6M | $4.0M | $1.5M | $2.9M | $28.3M | 0 | 0 | 0 | 0 |
| Cost of Revenue | $3.7M | $3.2M | $380000 | $1.1M | $1.8M | $1.2M | $1.1M | $1.2M | $1.2M | $1.1M |
| Gross Profit | $3.6M | $3.4M | $3.6M | $351000 | $1.1M | $27.1M | -$1.1M | -$1.2M | -$1.2M | -$1.1M |
| Research & Development | 0 | $196008 | $9.2M | $29.8M | $38.9M | $48.6M | $17.0M | $22.7M | $33.7M | $24.9M |
| Selling, General & Admin | $4.0M | $3.6M | $8.8M | $9.2M | $17.5M | $17.8M | $5.6M | $11.9M | $11.3M | $12.8M |
| Operating Expenses | $4.0M | $3.8M | $18.0M | $38.9M | $56.3M | $66.4M | $22.7M | $34.6M | $43.8M | $36.6M |
| Operating Income | -$419220 | -$397800 | -$14.3M | -$38.6M | -$55.3M | -$39.3M | -$23.7M | -$35.7M | -$45.0M | -$37.7M |
| EBITDA | $2.0M | $62540 | -$14.3M | -$40.2M | -$70.6M | -$51.9M | -$23.6M | -$33.0M | -$50.3M | -$37.3M |
| Interest Expense | $307450 | $300432 | 0 | 0 | $8.8M | $876442 | $3.6M | $1.1M | $455000 | $1.1M |
| Pre-tax Income | $1.2M | $1.7M | -$20.0M | -$40.7M | -$80.1M | -$54.6M | -$28.2M | -$35.2M | -$51.9M | -$39.6M |
| Income Tax | $201858 | $452778 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | $307303 | $632241 | -$20.0M | -$40.7M | -$80.1M | -$26.4M | -$28.2M | -$35.2M | -$51.9M | -$39.6M |
| EPS | $50.21 | $103.31 | $-6.79 | $-1.50 | $-1.93 | $-19.32 | $-9.10 | $-6.96 | $-4.25 | $-2.58 |
| EPS (Diluted) | $50.21 | $103.31 | $-6.79 | $-1.50 | $-1.93 | $-19.32 | $-9.10 | $-6.96 | $-4.25 | $-2.58 |
| Shares Outstanding (Diluted) | $6120 | $6120 | $2.9M | $8.2M | $8.2M | $3.2M | $3.1M | $5.1M | $12.2M | $15.3M |
Balance Sheet (10y)
| Year | 2012 | 2013 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.4M | $2.1M | $25.5M | $5.6M | $34.6M | $88.8M | $7.8M | $12.9M | $17.6M | $18.6M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $580378 | $485762 | $107000 | $440000 | $5.0M | $806000 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $2.1M | $2.6M | $25.7M | $6.1M | $40.3M | $91.2M | $10.7M | $16.3M | $20.7M | $19.3M |
| Property, Plant & Equipment | $6.6M | $6.2M | $17000 | $4.8M | $4.2M | $4.4M | $8.5M | $7.3M | $6.2M | $5.1M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $11.0M | $11.1M | $26.6M | $11.9M | $47.3M | $96.5M | $22.7M | $27.1M | $28.2M | $25.9M |
| Accounts Payable | $209516 | $37622 | $534000 | $11.2M | $5.6M | $4.7M | $2.8M | $4.4M | $1.0M | $672000 |
| Short-term Debt | $115582 | $122182 | 0 | $6.9M | $80.6M | $952000 | $692000 | 0 | $901000 | 0 |
| Total Current Liabilities | $1.1M | $1.1M | $7.4M | $26.6M | $107.4M | $11.3M | $6.9M | $9.8M | $11.5M | $8.1M |
| Long-term Debt | $5.3M | $5.2M | 0 | 0 | $635000 | 0 | 0 | 0 | $20.0M | $9.4M |
| Total Liabilities | $6.8M | $6.6M | $7.7M | $30.5M | $137.8M | $15.0M | $13.7M | $15.8M | $39.5M | $24.2M |
| Retained Earnings | $1.7M | $2.3M | -$39.8M | -$80.5M | -$160.6M | -$215.1M | -$107.0M | -$142.2M | -$194.1M | -$233.7M |
| Total Equity | $1.7M | $2.3M | $18.9M | -$18.6M | -$90.4M | $81.5M | $8.9M | $11.4M | -$11.3M | $1.6M |
| Total Debt | $5.4M | $5.3M | 0 | $10.8M | $85.0M | $4.7M | $7.5M | $6.9M | $26.0M | $14.5M |
| Net Debt | $4.0M | $3.3M | -$25.5M | $5.2M | $50.4M | -$84.1M | -$316000 | -$6.0M | $8.4M | -$4.1M |
| Working Capital | $959801 | $1.5M | $18.3M | -$20.5M | -$67.1M | $80.0M | $3.8M | $6.6M | $9.2M | $11.2M |
Cash Flow (10y)
| Year | 2012 | 2013 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $307303 | $632241 | -$20.0M | -$40.7M | -$80.1M | -$26.4M | -$28.2M | -$35.2M | -$51.9M | -$39.6M |
| Depreciation & Amortization | $463216 | $460344 | $2000 | $496000 | $628000 | $251451 | $1.1M | $1.2M | $1.2M | $1.1M |
| Stock-based Compensation | 0 | 0 | 0 | 0 | 0 | $617756 | $579000 | $1.2M | $1.5M | $2.7M |
| Change in Working Capital | -$74976 | $332643 | $3.1M | $9.8M | $25.8M | $872435 | -$150000 | -$57000 | $4.0M | -$3.4M |
| Operating Cash Flow | $1.1M | $1.9M | -$8.0M | -$24.6M | -$22.9M | -$23.9M | -$22.2M | -$32.7M | -$37.1M | -$37.0M |
| Capital Expenditure | -$47734 | -$17575 | 0 | -$242000 | -$41000 | -$525359 | -$654000 | -$66000 | -$87000 | -$16000 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock Repurchased | 0 | 0 | 0 | -$375000 | -$36000 | 0 | 0 | -$150000 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | $1.0M | $1.9M | -$8.0M | -$24.8M | -$22.9M | -$24.5M | -$22.8M | -$32.8M | -$37.2M | -$37.0M |
Growth & Margins (10y)
| Year | 2012 | 2013 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth (YoY) | -9.8% | -38.8% | -63.1% | +93.7% | +883.1% | -100.0% | ||||
| Net Income Growth (YoY) | +105.7% | -3267.3% | -103.0% | -97.0% | +67.0% | -6.8% | -24.8% | -47.5% | +23.8% | |
| EPS Growth (YoY) | +105.8% | -106.6% | +77.9% | -28.7% | -901.0% | +52.9% | +23.5% | +38.9% | +39.3% | |
| Shares Change (YoY) | +0.0% | +48077.3% | +176.4% | +0.0% | -60.7% | -3.1% | +63.1% | +141.3% | +25.5% | |
| FCF Growth (YoY) | +84.3% | -527.8% | -209.6% | +7.7% | -6.7% | +6.7% | -43.5% | -13.4% | +0.5% | |
| Gross Margin | 49.7% | 51.8% | 90.6% | 23.6% | 36.9% | 95.6% | ||||
| Operating Margin | -5.7% | -6.0% | -356.0% | -2595.2% | -1919.2% | -138.8% | ||||
| EBITDA Margin | 26.9% | 1.0% | -355.9% | -2700.9% | -2452.5% | -183.4% | ||||
| Net Margin | 4.2% | 9.6% | -497.0% | -2734.2% | -2781.5% | -93.2% | ||||
| FCF Margin | 13.9% | 28.5% | -199.1% | -1669.9% | -796.1% | -86.4% | ||||
| Effective Tax Rate | 16.9% | 26.1% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Per-Share Data (10y)
| Year | 2012 | 2013 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| FCF Per Share | $166.25 | $306.33 | $-2.72 | $-3.05 | $-2.81 | $-7.65 | $-7.37 | $-6.48 | $-3.04 | $-2.41 |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | $6120 | $6120 | $2.9M | $8.2M | $8.2M | $3.2M | $3.1M | $5.1M | $12.2M | $15.3M |
What to look at in Biotech
Most small biotechs lose money. Analysing them with P/E makes no sense — look at cash and pipeline.
- Cash Runway — Months of cash at current burn rate. <18 months = urgent dilution risk
- Annual cash burn — Rate at which they burn operating cash. Compare with cash position to project runway
- Total Debt — Biotech with no revenue + debt = recipe for bankruptcy
- R&D / Market cap — How much they invest in pipeline vs the company value — research-intensity indicator
- Market cap / Cash — If it trades near its cash, the market assigns ~0 value to the pipeline — opportunity or trap
Profitability
| Return on Equity | -1266.43% |
| Return on Invested Capital | -163.43% |
| Return on Assets | -120.78% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Debt / Equity | 1.78 |
| Current Ratio | 2.77 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -13.92 |
Key Ratios (10y)
| Year | 2012 | 2013 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E | 0.12 | 0.06 | -0.87 | -3.93 | -3.05 | -0.30 | -0.65 | -1.20 | -1.20 | -3.09 |
| P/B | 0.02 | 0.02 | 0.92 | -2.58 | -0.53 | 0.23 | 2.05 | 3.71 | -5.50 | 74.50 |
| P/S | 0.00 | 0.01 | 4.31 | 32.28 | 16.67 | 0.67 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Margin | 49.7% | 51.8% | 90.6% | 23.6% | 36.9% | 95.6% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Margin | -5.7% | -6.0% | -356.0% | -2595.2% | -1919.2% | -138.8% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Margin | 4.2% | 9.6% | -497.0% | -2734.2% | -2781.5% | -93.2% | 0.0% | 0.0% | 0.0% | 0.0% |
Related companies: ACTU · APLT · CRBP · CRDF · MIST · MOLN · NKTX
Explore sector: Healthcare · Biotechnology
More sections of ELTX: Overview · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks